Cita APA

E, S., S, M., J, S., J, S., HA, A., M, P., . . . R, F. (2026). Metabolomics reveals LysoPC a C17: 0 (LPC 17:0) as candidate biomarker for personalized medicine in morbid obesity.

Citación estilo Chicago

E, Stefanini, Marin S, Serrano-Marín J, Sánchez-Navés J, Alkozi HA, Pallàs M, Cascante M, Griñán-Ferré C, y Franco R. Metabolomics Reveals LysoPC a C17: 0 (LPC 17:0) As Candidate Biomarker for Personalized Medicine in Morbid Obesity. 2026.

Cita MLA

E, Stefanini, et al. Metabolomics Reveals LysoPC a C17: 0 (LPC 17:0) As Candidate Biomarker for Personalized Medicine in Morbid Obesity. 2026.